Detalhe da pesquisa
1.
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study.
Ann Hematol
; 2024 Apr 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38609726
2.
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
Cancer
; 129(7): 992-1004, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36692409
3.
Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML.
Blood
; 138(25): 2696-2701, 2021 12 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34343258
4.
BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study.
Haematologica
; 109(3): 988-993, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37794811
5.
Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analyses.
Br J Haematol
; 183(1): 47-59, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30022491
6.
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.
Ann Hematol
; 97(6): 1009-1018, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29442162
7.
Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL).
Ann Hematol
; 97(5): 791-798, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29411126
8.
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.
Blood
; 125(22): 3455-65, 2015 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-25795919
9.
VEXAS-like syndrome: a potential new entity?
Ann Hematol
; 101(5): 1125-1128, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35318504
10.
Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996.
Am J Hematol
; 96(9): E334-E338, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34048072
11.
Erythrocytapheresis is a valid and safe therapeutic option in dysmetabolic iron overload syndrome.
J Clin Apher
; 31(5): 443-7, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26411360
12.
Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.
Br J Haematol
; 168(5): 689-700, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25376846
13.
Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
Eur J Haematol
; 93(3): 207-13, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24673398
14.
The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors.
Expert Opin Pharmacother
; 24(13): 1449-1461, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37341682
15.
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine.
Front Oncol
; 13: 1117815, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36865808
16.
A case of high-risk AML in a patient with advanced systemic mastocytosis.
Clin Case Rep
; 11(7): e7134, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37469366
17.
Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experience.
Front Immunol
; 14: 1195734, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37809082
18.
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data.
Healthcare (Basel)
; 11(10)2023 May 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37239765
19.
Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up.
Hematol Oncol
; 30(4): 180-5, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22189677
20.
Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting.
J Clin Med
; 11(24)2022 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36556033